Finally, to evaluate if silencing of NME2 could enhance the negative effect of MYC inhibition on tumor cell metastatic potential, we performed Boyden chamber-based in vitro migration assay using C42B-EnzaRes cells (see Methods), which demonstrated that cell migration was further reduced when NME2 knockdown was added to MYCi975 administration (Fig. 7f). The gene discussed is NME2; the disease is neoplasm.